InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,319.31
(
2.30%
)
US TECH 100
18,010.00
(
0.49%
)
Dow Jones
39,446.49
(
1.76%
)
Brent Oil
79.30
(
0.70%
)
Bitcoin
60,498.65
(
-2.00%
)
Post# of 252816
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next

mcbio

Send PM Follow Ignore
Followers 69
Posts 6152
Boards Moderated 0
Alias Born 11/26/2008

mcbio

Re: DewDiligence post# 111138

Monday, 12/20/2010 9:15:33 PM

Monday, December 20, 2010 9:15:33 PM

Post# of 252816

Here’s the 12/20/10 Goldman Sachs report on MNTA

I'm sorry but I'm having a hard time equating "low probability of a competitor approval in the next few years" (with respect to mLovenox) and "high probability of generic Copaxone approval" (without even considering the rest of the pipeline) to a $15 12-month price target.

Public Reply Private Reply New Post
Keep Last Read
Replies (4) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (4) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up